ARTICLE | Company News
Merck doubling down on biotech hubs
July 13, 2016 12:47 AM UTC
Merck & Co. Inc. (NYSE:MRK) plans to reduce its workforce by undisclosed amounts at its Kenilworth, N.J., and Rahway, N.J., sites, as well as its North Wales, Pa., screening facility. The company said the moves are part of a strategy to consolidate work on Merck Research Laboratories' programs at facilities in Cambridge, Mass., and the San Francisco Bay Area.
Late this year, Merck expects to open a new Cambridge laboratory that will focus on emerging science including the microbiome and host-pathogen interactions. A Bay Area facility focused on cardiometabolic disease and oncology discovery is to open in early 2017. ...